Results 161 to 170 of about 742,802 (244)

Surveillance for Acute Viral Hepatitis : United States, 2006 [PDF]

open access: yes
"Problem/Condition: In the United States, acute viral hepatitis most frequently is caused by infection with three viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

Purification and concentration of model viruses using single‐pass tangential flow filtration

open access: yesBiotechnology Progress, EarlyView.
Single‐pass TFF was developed for an enveloped and non‐enveloped virus for use in continuous downstream purification processes. Enveloped virus was concentrated and purified. Abstract The vaccine and viral vector industry is growing at an accelerated rate.
Luis Alberto Mejía‐Manzano   +6 more
wiley   +1 more source

Surveillance for Acute Viral Hepatitis, United States, 2005 [PDF]

open access: yes
" Problem/Condition: In the United States, acute viral hepatitis most frequently is caused by infection with hepatitis A Virus (HAV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV).

core  

Status and future of recombinant adeno‐associated virus vector manufacturing

open access: yesBiotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Serological Profile of Hepatitis B, C, and D and Factors Associated With Hepatitis B Exposure and Vaccination Among Hemodialysis Patients in Northeastern Brazil

open access: yesInternational Journal of Nephrology
Lucas Lima da Silva   +11 more
doaj   +1 more source

Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins

open access: yesBiotechnology Progress, EarlyView.
Virus‐like particle vaccines displaying spike proteins from OC43, HKU1 A, and HKU1 B were evaluated in mice for their ability to elicit antibodies against the spike proteins from OC43, HKU1 A, HKU1 B, and HKU1 C. Abstract Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in ...
Peter J. Halfmann   +6 more
wiley   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann   +4 more
wiley   +1 more source

Diagnostic Usefulness of Cell Block Samples in Fluid Overload‐Associated Large B‐Cell Lymphoma

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Fluid overload‐associated B‐cell lymphoma (FO‐LBCL) is a B‐cell neoplasm that presents as serous effusions without detectable tumor masses and Kaposi sarcoma‐associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8) infection. Here, we report a case of an 81‐year‐old female patient with FO‐LBCL (Stage IVA) who presented with pericardial and ...
Hiroyuki Okanishi   +14 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy